Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | Tamibarotene (SY-1425) and VIDAZA (azaciditine) - (SELECT-MDS-1) | Myelodysplastic Syndrome | Phase 3 | Trial Discontinued | Oral and subcutaneous | Hematology |
| Syros Pharmaceuticals Inc. | SY-2101 | Acute Promyelocytic Leukemia (APL) | Phase 3 | Trial Discontinued | Oral | Oncology |
| Syros Pharmaceuticals Inc. | Tamibarotene (SY-1425) with VENCLEXTA (venetoclax) and VIDAZA (azacitidine) - (SELECT-AML-1) | Acute myeloid leukemia (AML) | Phase 2 | Data Released | Oral | Oncology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Fazirsiran (TAK-999/ARO-AAT) - (REDWOOD) | Alpha-1 antitrypsin deficiency (AATD-LD) | NDA Filing | Data Released | Intravenous | Genetic Disorder |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Rusfertide - (VERIFY) | Polycythemia vera | NDA Filing | Ongoing | Subcutaneous | Hematology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Rusfertide - (VERIFY) | Polycythemia vera | NDA Filing | Ongoing | Subcutaneous | Hematology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | QDENGA (TAK-003) - (TIDES) | Dengue Vaccine | NDA Filing | Withdrawn | Subcutaneous | Immunology |
| Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) | Oveporexton (TAK-861-2001) | Narcolepsy type 1 (NT1) | NDA Filing | Data Released | Oral | Neurology |
